Orrick, Herrington & Sutcliffe partner E. Joshua Rosenkranz is known as “the defibrillator” for his ability to revive cases from the dead on appeal. But his latest patient may be beyond saving, based on arguments Friday before the U.S. Court of Appeals for the Federal Circuit.

Two of the three judges hearing Bio-Rad Laboratories v. 10x Genomics sounded skeptical of Rosenkranz’s arguments that 10x Genomics Inc.’s ground-breaking single-cell technology doesn’t infringe three Bio-Rad Laboratories Inc. patents, or that a Delaware jury’s award of $24 million and a 15% royalty were beyond the pale.